Loading...

IXICO plc

IXI.LLSE
HealthcareBiotechnology
$12.20
$0.95(8.44%)

IXICO plc (IXI.L) Stock Overview

Explore IXICO plc’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth
-13.49%
13.49%
Profit Growth
$-0.04
69.86%
EPS Growth
$-0.04
100.00%
Operating Margin
-46.46%
49.90%
ROE
-20.52%
69.86%
Dividend Yield
0.00%
Analyst Recommendations data is not available for IXI.LAnalyst Recommendations details for IXI.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

IXICO plc provides data analytics services to the biopharmaceutical industry in the United Kingdom, Switzerland, Netherlands, Ireland, rest of Europe, the United States, and internationally. Its services include collection, analysis, management, and reporting on data generated in the course of a clinical study. The company's technologies comprise Assessa, a secure online digital platform that provides clinical decision support for patient selection and post-marketing surveillance; and TrialTracker, a platform that delivers imaging services designed to manage the complex imaging workflow from image upload, quality control, and reading/analysis to reporting and data transfer. Its focused therapeutic areas include Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis and other demyelinating diseases, Progressive Supranuclear Palsy, and other rare neurological diseases. The company also engages in the data collection, optimization, and analytics of rare neurological disorders; offers drug development analytics, imaging operation services, and post marketing surveillance services, as well as consultancy services; and provides end-to-end services, such as trail design and consultation, project management, imaging site set-up and management, data management, reading and analysis, and regulatory pathway. IXICO plc was incorporated in 1995 and is based in London, the United Kingdom.

CEO

Mr. Bram Goorden M.Sc.

Employees

81

Headquarters

Griffin Court, London

Founded

1996

Frequently Asked Questions

Meyka LogoMeyka

Meyka is the best Alternative Data platform powered by AI providing research insights for investors

Connect With Us

Legal Disclaimer

The information provided by Meyka AI PTY LTD is for informational and research purposes only and does not constitute financial, investment, or trading advice. Meyka is a research platform, not a financial advisory service. Investing in financial markets involves risks, and past performance does not guarantee future results. Users should conduct their own due diligence, consult with professional financial advisors, and assess their risk tolerance before making investment decisions. Meyka and its operators are not liable for any financial losses incurred from the use of information on this platform. The data provided is derived from publicly available sources and is believed to be reliable but may not always be accurate or up to date. Users should independently verify information and not rely solely on Meyka for financial decisions. By using Meyka, you acknowledge that it does not provide financial advice or recommendations and agree to seek guidance from a qualified financial professional before making any investment decisions.

© 2025 Meyka AI PTY LTD. All rights reserved.